Rani Therapeutics Holdings, Inc. (RANI)

NASDAQ: RANI · USD

$0.61

+0.00 (0.0%)· Recorded snapshot

Market cap	84.9M
Revenue (ttm)	4.9M
Net income (ttm)	-30.1M
EPS (ttm)	-$0.22
Shares out	139.4M
Volume	319,156
Beta	0.71

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.9M
Net income (ttm): -30.1M
EPS (ttm): -$0.22
Market cap: 84.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-172.1

P25 n/aP50 n/aP75 n/a

ROIC-64.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All RANI indicators

Market & fundamental data

Available fields

200

Groups with data

Currency

USD

Showing 200 of 200 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001856725
Company name	Rani Therapeutics Holdings, Inc.
Country	United States
Country code	US
CUSIP number	753018100
Earnings date	2026-11-09
Earnings time	bmo
Employees	71
Employees change	-35
Employees growth	-33.02%
Enterprise value	$35.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2012
Industry	Biotechnology
IPO date	2021-07-30
Is primary listing	Yes
Is SPAC	No
ISIN number	US7530181004
Last 10-K release date	2026-03-26
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$84.9M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$0.61
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RANI
U.S. state	California
Website	https://www.ranitherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-35.68%
EV/Sales	6.99x
FCF / EV yield	-59.64%
FCF yield	-24.23%
Forward EV/Sales	11.96x
Forward P/S	29.44x
P/B ratio	1.75x
P/S ratio	17.21x
Price / tangible book value	2.14x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-675.8%
Pretax margin	-685.34%
Profit per employee	$-424,521
Revenue per employee	$68,690
ROA	-52.99%
ROA (5Y)	-46.29%
ROCE	-65.65%
ROE	-172.15%
ROE (5Y)	-165.86%
ROIC	-64.38%
SBC / revenue	186.36%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	6
EPS growth years	2
Gross profit growth	306.42%
Gross profit growth 5Y	9.95%
Net income growth years	2
Revenue growth	306.42%
Revenue growth (QoQ)	0%
Revenue growth 5Y	9.95%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-47,000
Depreciation and amortization	$722,000
EBIT	$-33M
EBITDA	$-32.2M
EPS	$-0.22
FCF per share	$-0.15
Financing cash flow	$62.6M
Free cash flow	$-20.3M
Free cash flow minus SBC	$-29.4M
Gross profit	$4.9M
Investing cash flow	$-48M
Net borrowing	$-13.2M
Net cash flow	$-5.6M
Net income	$-30.1M
Operating cash flow minus SBC	$-29.4M
Operating income	$-33M
Revenue	$4.9M
Stock-based compensation	$9.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.15
Book value per share	$0.35
Debt / equity	0.07
Interest coverage	-28.22
Long-term assets	$4.3M
Long-term liabilities	$2.2M
Net cash (debt)	$49.8M
Net cash / market cap	59.38%
Net debt / equity	-1.04
Piotroski F-Score	3
Property, plant and equipment	$4.1M
Shareholders' equity	$48M
Tangible book value	$39.2M
Tangible book value per share	$0.35
Total assets	$60.8M
Total cash	$53.4M
Total debt	$3.5M
Total liabilities	$12.9M
WACC	8.89%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.13
Current assets	$56.5M
Current liabilities	$10.6M
Current ratio	5.31
Net working capital	$-6.2M
Quick ratio	5.23
Working capital	$45.9M
Working capital turnover	0.27

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-321.63%
Dividend yield	0%
Shareholder yield	-321.63%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$0.82
1D price change	0%
1M price change	-19.32%
1M total return	-19.32%
1W price change	-6.17%
1W total return	-6.17%
1Y price change	-65.59%
1Y return CAGR	-65.61%
1Y total return	-65.59%
20-day SMA	$0.70
200-day SMA	$0.94
3M price change	-24.39%
3M total return	-24.39%
3Y price change	-68.67%
3Y return CAGR	-32.07%
3Y total return	-68.67%
50-day SMA	$0.78
50-day SMA vs 200-day SMA	50under200
52-week high	$2.63
52-week high date	2025-11-06
52-week low	$0.57
52-week low date	2026-10-22
5Y price change	-97.33%
5Y return CAGR	-51.55%
5Y total return	-97.33%
6M price change	-31.17%
6M total return	-31.17%
All-time high	$36.27
All-time high date	2021-11-15
All-time low	$0.39
All-time low date	2025-07-15
Average true range (ATR)	$0.05
Average volume	525.4K
Beta (1Y)	2.05
Beta (2Y)	2.27
Beta (5Y)	0.71
Change from 52-week high	-76.83%
Change from 52-week low	6.21%
Change from all-time high	-98.31%
Change from all-time low	58.28%
Change from open	1.63%
Day's gap	-1.61%
Dollar volume	$194,462
High price	$0.61
Low price	$0.60
Monthly RSI	40.82
Open price	$0.60
Position in 52-week range	100%
Premarket change	-0.28%
Premarket close	$0.61
Premarket price	$0.61
Premarket volume	3.7K
Previous close	$0.61
Price vs 150-day SMA	-25.56%
Price vs 20-day SMA	-12.67%
Price vs 200-day SMA	-34.9%
Price vs 50-day SMA	-21.45%
Relative volume	0.61
Return from IPO open	-94.65%
Return from IPO price	-94.53%
RSI	33.83
Sharpe ratio	-0.62
Sharpe ratio (3Y)	0.31
Sharpe ratio (5Y)	0.02
Sortino ratio	-0.96
Sortino ratio (3Y)	0.86
Sortino ratio (5Y)	0.1
Volume	319.2K
Weekly RSI	35.9
YTD price change	-54.63%
YTD total return	-54.63%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	82.3M
Float percentage	59.05%
Shares change (QoQ)	3.98%
Shares change (YoY)	321.63%
Shares held by insiders	3.75%
Shares held by institutions	25.28%
Shares outstanding	139.4M
Short % of float	8.81%
Short % of shares	5.2%
Short ratio	13.1 days

Deeper analysis on RANI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RANI report

Is a complete RANI research report available?

No complete published report is available for Rani Therapeutics Holdings, Inc. (RANI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Rani Therapeutics Holdings, Inc. (RANI)

Price

Financial snapshot

Fair-value bridge

Latest news · RANI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RANI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RANI

Frequently asked questions